(4,5-bis(benzyloxy)pyridin-2-yl)methanol | 112334-43-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4,5-bis(benzyloxy)pyridin-2-yl)methanol
• 英文别名: 4,5-bis(phenylmethoxy)-2-pyridinemethanol；[4,5-bis(phenylmethoxy)pyridin-2-yl]methanol
• CAS: 112334-43-7
• 化学式: C₂₀H₁₉NO₃
• 分子量: 321.376
• InChiKey: NNEDRWCGFQMNLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  51.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4,5-bis(benzyloxy)pyridin-2-yl)methanol 在 三乙基硅烷 、 甲酸 、 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 hydrazine hydrate 、 三丁基膦 、 偶氮二甲酸二异丙酯 、 三氧化硫吡啶 、 三氯化硼 、 sodium hydride 、 碳酸氢钠 、 三乙胺 、 间氯过氧苯甲酸 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 乙醇 、 正己烷 、 二氯甲烷 、 甲基叔丁基醚 、 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 35.83h， 生成 (S)-3-((Z)-2-(2-aminothiazol-4-yl)-2-(((S)-1-(1,5-dihydroxy-4-oxo-1,4-dihydropyridin-2-yl)-2-(methylthio)ethoxy)imino)acetamido)-2,2-dimethyl-4-oxoazetidin-1-yl hydrogen sulfate
  参考文献：
  名称：

  Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections

  摘要：

  Conjugating a siderophore to an antibiotic is a promising strategy to overcome the permeability-mediated resistance of Gram-negative pathogens. On the basis of the structure of BAL30072, novel pyridone-conjugated mono-sulfactams incorporating diverse substituents into the methylene linker between the 1,3-dihydroxypyridin-4(1H)-one and the aminothiazole oxime were designed and synthesized. Structure activity relationship studies revealed that a variety of substituents were tolerated, with isopropyl (compound 12c) and methylthiomethyl (compound 16a) showing the best efficacy against multidrug-resistant (MDR) Gram-negative pathogens. In addition, compound 12c exhibits a good free fraction rate in an in vitro human plasma protein binding test, along with a low clearance and favorable plasma exposure in vivo. In a murine systemic infection model with MDR Klebsiella pneumoniae, compound 12c shows an ED50 of 10.20 mg/kg. Taken together, the results indicate that compound 12c is a promising drug candidate for the treatment of serious infections caused by MDR Gram-negative pathogens.

  DOI：

  10.1021/acs.jmedchem.6b01261
• 作为产物：
  描述：

  4,5-二苄氧基吡啶甲酸苄酯 在 sodium tetrahydroborate 、 乙醇 作用下， 以 乙醇 为溶剂， 以92%的产率得到(4,5-bis(benzyloxy)pyridin-2-yl)methanol
  参考文献：
  名称：

  [EN] MONOBACTAMS
  [FR] MONOBACTAMES

  摘要：

  本发明涉及一类新的单环内酰胺衍生物及其用于治疗细菌感染的用途。

  公开号：

  WO2012073138A1

文献信息

• 6- or 7-beta-[2-[4-(substituted)-2,3-dioxopiperazin-1-yl) carbonylamino]-(substituted)acetamido]-penicillin and cephalosporin derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0293532A1

  公开（公告）日：1988-12-07

  Antibacterial agents have the formula (I) or are pharmaceutically acceptable salts or in vivo hydrolysable esters thereof: in which Y¹ is oxygen, sulphur or -CH₂ and Z represents hydrogen, halogen, C1-4 alkoxy, -CH₂-Q or -CH=CH-Q where Q represents hydrogen, halogen, hydroxy, mercapto, cyano, carboxy, carboxylic ester, C1-4 alkyloxy, acyloxy, aryl, a heterocyclyl group bonded via carbon, a heterocyclylthio group or a nitrogen containing heterocyclic group bonded via nitrogen; R⁵ represents phenyl, substituted phenyl, cyclohexenyl, cyclohexadienyl or an optionally substituted 5 or 6-membered heterocyclic ring containing up to three hetero atoms selected from oxygen, sulphur or nitrogen, R⁶ is hydrogen, hydroxymethyl, formamido, or methoxy, R⁷ and R⁸ are the same or different and represent hydrogen, C1-6 alkyl, substituted C1-6 alkyl, halogen, amino, phenyl, substituted phenyl, hydroxy or C1-6 alkoxy or R⁷ and R⁸ form the residue of an optionally substituted 5 or 6- membered carbocyclic ring or a 5 or 6-membered heterocyclic ring containing up to three hetero atoms selected from oxygen, sulphur or nitrogen, R⁹ is wherein R¹⁰ and R¹¹ are the same or different and each represents hydroxy, or protected hydroxy and XR⁹ is -(CH₂)nR⁹, -NHCOR⁹, -N=CHR⁹, -NHCH₂R⁹, or -COR⁹, where n is from 0 to 2; with the proviso that XR⁹ does not represent -N=CHR⁹ when R⁶ represents hydrogen. The use of the compounds is described together with intermediates for their preparation.

  抗菌剂的化学式为（I），或者是其药用可接受盐或体内水解酯： 其中Y¹为氧、硫或-CH₂，Z代表氢、卤素、C1-4烷氧基、-CH₂-Q或-CH=CH-Q，其中Q代表氢、卤素、羟基、巯基、氰基、羧基、羧酸酯、C1-4烷氧基、酰氧基、芳基、通过碳键合的杂环基、杂环硫基或通过氮键合的含氮杂环基； R⁵代表苯基、取代苯基、环己烯基、环己二烯基或一个可选择取代的含有最多三个氧、硫或氮杂原子的5或6元杂环环，R⁶为氢、羟甲基、甲酰胺基或甲氧基，R⁷和R⁸相同或不同，代表氢、C1-6烷基、取代C1-6烷基、卤素、氨基、苯基、取代苯基、羟基或C1-6烷氧基，或R⁷和R⁸形成一个可选择取代的5或6元碳环或一个含有最多三个氧、硫或氮杂原子的5或6元杂环环，R⁹为 其中R¹⁰和R¹¹相同或不同，每个代表羟基或保护羟基，XR⁹为-(CH₂)nR⁹、-NHCOR⁹、-N=CHR⁹、-NHCH₂R⁹或-COR⁹，其中n为0至2；但XR⁹不代表-N=CHR⁹当R⁶代表氢时。 描述了这些化合物的用途以及其制备的中间体。
• 2-oxo-1-[[(substituted sulfonyl)amino]carbonyl]azetidines
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04743685A1

  公开（公告）日：1988-05-10

  Antibacterial activity is exhibited by 2-azetidinones having a 3-acylamino substituent and having an activating group in the 1-position of the formula ##STR1##

  2-氮杂环丙酮具有3-酰氨基取代基并在分子式的1位具有活化基团，表现出抗菌活性。
• [EN] MONOCYCLIC Β-LACTAM-IRON CARRIER CONJUGATE, AND MANUFACTURING METHOD AND APPLICATION THEREOF<br/>[FR] CONJUGUÉ DE SUPPORT DE BÊTA-LACTAME-FER MONOCYCLIQUE, PROCÉDÉ DE PRODUCTION ET APPLICATION ASSOCIÉE<br/>[ZH] 单环β-内酰胺-铁载体轭合物及其制备方法和用途
  申请人：SHANGHAI INST MATERIA MEDICA CAS

  公开号：WO2018014823A1

  公开（公告）日：2018-01-25

  提供如下通式(I)所示的单环β-内酰胺-铁载体轭合物，其光学异构体或其药学上可接受的盐，以及其合成方法和其在治疗细菌感染性疾病中的用途。
• Pyridone-Conjugated Monobactam Antibiotics with Gram-Negative Activity
  作者：Matthew F. Brown、Mark J. Mitton-Fry、Joel T. Arcari、Rose Barham、Jeffrey Casavant、Brian S. Gerstenberger、Seungil Han、Joel R. Hardink、Thomas M. Harris、Thuy Hoang、Michael D. Huband、Manjinder S. Lall、M. Megan Lemmon、Chao Li、Jian Lin、Sandra P. McCurdy、Eric McElroy、Craig McPherson、Eric S. Marr、John P. Mueller、Lisa Mullins、Antonia A. Nikitenko、Mark C. Noe、Joseph Penzien、Mark S. Plummer、Brandon P. Schuff、Veerabahu Shanmugasundaram、Jeremy T. Starr、Jianmin Sun、Andrew Tomaras、Jennifer A. Young、Richard P. Zaniewski

  DOI：10.1021/jm400560z

  日期：2013.7.11

  Herein we describe the structure-aided design and synthesis of a series of pyridone-conjugated monohactam analogues with in vitro, antibacterial activity against clinically relevant Grain-negative species including Pseuedomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Rat pharmacokinetic studies with,compound 17 demonstrate low clearance and low plasma protein binding. In addition evidence is provided for a number of analogues suggesting that the siderophore receptors PiuA and PirA play a role in drug uptake in P. aeruginosa strain PAO1.
• MONOCYCLIC B-LACTAM-IRON CARRIER CONJUGATE, AND MANUFACTURING METHOD AND APPLICATION THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP3489234B1

  公开（公告）日：2020-03-18